Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001050926 | SCV001215056 | uncertain significance | Glycogen storage disease, type II | 2022-07-26 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 931 of the GAA protein (p.Asp931Asn). This variant is present in population databases (rs756199247, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with GAA-related conditions. ClinVar contains an entry for this variant (Variation ID: 847393). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt GAA protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV001759783 | SCV001996312 | uncertain significance | not provided | 2019-09-23 | criteria provided, single submitter | clinical testing | Not observed at a significant frequency in large population cohorts (Lek et al., 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Genome- |
RCV001050926 | SCV002027316 | uncertain significance | Glycogen storage disease, type II | 2021-09-05 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV001759783 | SCV003828497 | uncertain significance | not provided | 2021-07-23 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001050926 | SCV002094487 | uncertain significance | Glycogen storage disease, type II | 2020-03-13 | no assertion criteria provided | clinical testing |